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Purpose of review The aim of this article is to describe recent observations regarding the basis for the initiation and disease evolution of multiple sclerosis. Recent findings A current debate is where and what initiates the neuroinflammatory reaction that characterizes the acute multiple sclerosis lesion. Immune sensitization to neural antigens could develop within the systemic compartment consequent to exposure to cross-reacting, possibly viral derived, peptides (molecular mimicry). Although CD4 T cells are considered central to initiating central nervous system inflammation, the actual extent and specificity of tissue injury reflects the array of adaptive (CD8 T cells and antibody) and innate (microglia/macrophages) immune constituents present in the lesions. Neuropathologic studies indicate that lethal changes in neural cells (oligodendrocytes) could also be the initiating event, reflecting as yet unidentified acquired insults (e.g. exogenous virus or reactivated endogenous retrovirus) or intrinsic abnormalities ('neurodegenerative' hypothesis). Recurrence or persistence of the disease process can reflect events occurring at multiple sites including expansion of the immune repertoire in response to neural antigens transported to regional lymph nodes (determinant spreading), especially if immune regulatory mechanisms are defective; alterations in blood-brain barrier properties consequent to initial cellular transmigration; and participation of endogenous (microglia, astrocytes) or long lived infiltrating cells (macrophages, B cells in ectopic germinal centers) in regulating and effecting immune functions within the central nervous system. Accumulating neurologic deficit reflects the balance between injury and repair; the latter also being negatively or positively (trophic support and clearance of tissue debris) impacted by inflammatory processes. Summary Understanding the full spectrum of multiple sclerosis presents a continuing challenge for both immunology and neurobiology.
Introduction
In this article we will consider emerging observations that reflect on the entire clinical spectrum of multiple sclerosis (MS), from its typical relapsing remitting initial course onset to its evolution into a progressive disorder. These observations provide new insights into the disease pathogenesis but also raise new questions and challenges.
Basis of disease initiation
The pathologic lesions that best correlate with acute clinical exacerbation of disease, feature foci of inflammation associated with active myelin degradation and phagocytosis. An ongoing issue is whether this neuroinflammatory reaction is initiated within the immune system or in response to primary events impacting on the neural cells.
Immune initiated disease hypothesis
This long favored hypothesis in MS implicates that autoreactive T cells generated in the systemic compartment access the central nervous system (CNS) where they persist and induce an inflammatory cascade that results in the injury of previously normal neural tissues. The animal model for this sequence is experimental autoimmune encephalomyelitis (EAE) which is initiated by systemic immunization with neural auto-antigens or by transfer of neural antigen sensitized T cells. The various EAE models show marked heterogeneity with regard to topography of lesions and extent of demyelination/axonal disruption, indicating the need to define mechanisms linking neuroinflammation and actual tissue injury [1] .
Initial studies regarding the frequency and properties of disease relevant immune constituents focused on CD4 [9] . Note that activated T cells, as found in MS lesions, can acquire non-MHC restricted cytotoxic capability mediated against neurons/ axons and myelinating cells [10 ,11,12] .
Myelin directed antibodies can contribute to the extent of tissue injury (demyelination) in experimental models of MS, but to date not initiate such disorders [13] . Disease relevant antibodies are present in lesions in at least some MS sub-types. Myelin specific antibodies can also be identified in the blood and CSF, although consensus is lacking regarding actual frequency or contribution to disease course or phenotype [14, 15 ] . Phenotypic and molecular studies of B cells recovered from the CSF early in the course of MS indicate that these cells are clonally expanded and antigen reactive, although the precise antigens remain to be defined [16, 17 ] . Antibody bound specifically (via Fab region) to neural cells could interact via their Fc portions with Fc receptor bearing cells (microglia/macrophages), thus directing the potential injury mediators produced by the latter toward a specific target.
Neural initiated disease hypothesis
This hypothesis implicates that events within the CNS initiate the MS disease process. A frequent speculation is that an acquired acute or persistent infection of neural cells could result in release of tissue antigens that in turn would provoke a disease relevant autoimmune response. The chronic inflammatory demyelinating disease induced by Theiler murine encephalomyelitis virus provides an example of such a disease development sequence. A role of direct infection-mediated cytotoxic neural injury would seem less likely given the apparent positive rather than negative effects of intense immunosuppression on lesion formation in MS. Other mechanisms whereby acquired infections could impact on MS include molecular mimicry responses, perturbing systemic immune regulatory properties, as might occur with Epstein-Barr virus infection of B cells [18] or MS retrovirus [19, 20] , and modulating immune related properties of glial cells via toll like receptor signaling [21] . Expression of persistent virus within the CNS could reflect a response to inflammation, an issue raised with regard to detection of human herpes virus-6 and human endogenous retroviruses (HERVs) in MS tissues [22, 23 ]. Increased expression of HERVs in astrocytes can result in release of mediators cytotoxic to oligodendrocytes [23 ] .
Barnett and Prineas [24 ] observed that changes in oligodendrocytes (caspase independent apoptosis) can be the initial events in formation of an acute MS lesion, serving to recruit an initial innate (microglia) and subsequently adaptive (T cell) immune response. The basis for the oligodendrocyte apoptosis is not defined but could reflect a primary cell injury, consistent with the previous discussion regarding CNS virus infection or other insults including trauma, or ischemia. In response to this report, Trapp [25] questioned 'whether the inflammatory demyelination is central to the pathogenesis of MS or is part of a cascade of adaptive immune responses that evolved as a critical component of tissue repair'. Therapies which deplete all circulating T cells in MS patients, such as intense immunosuppression requiring stem cell rescue or lympholytic anti-T cell monoclonal antibody (Campath-1) are associated with complete elimination of new inflammatory lesion formation [26 ,27] . Inherited disorders resulting in myelin disruption, particularly adrenoleukodystrophy, can feature a robust inflammatory response but to date there is little evidence that the disease course is altered by immunomodulatory therapy [28] .
Basis of disease recurrence and progression
Recurrent or persistent disease could reflect events that occur in the systemic immune system, at the blood-brain barrier (BBB), and in the CNS. Polymorphisms in an array of genes (MHC class II, NOS2A, CCR5d, CTL-A4, APOEe4) that impact on these parameters and that influence development and course of MS continue to be identified [29] [30] [31] [32] .
Systemic immune related events
Serial studies of peripheral blood T cells indicate that there is an expansion of the repertoire of antigens recognized over time (epitope and determinant spreading [33] ). In the intense immunosuppression/stem cell rescue cohort there is recovery over time of an even broader myelin reactive T cell repertoire raising the questions of whether and where memory cells persist or of where new antigen is being presented [26 ] . A number of factors could contribute to ongoing systemic immune reactivity. Neuroantigens can be transported from the CNS to cervical lymph nodes [34 ] via lymphatics that originate in the region of the olfactory bulb and reach peripheral lymphatic structures through the cribriform plate of the nasal bone. Activated T cells may have reduced requirements for co-stimulatory signals to respond to antigen presentation, and may serve as their own antigen presenting cells [35 ] . Circulating B cells in MS contain an increased proportion of activated memory cells that can serve antigen presentation functions and skew the T cell responses towards a specific cytokine profile [36 ]. An inborn or acquired functional deficit in regulatory cells, CD25
þ CD4 þ cells [37 ] and NKCD95 cells [38, 39] , could further contribute to disease recurrence.
Blood-brain barrier related events
The properties of the BBB that actively regulate recruitment of leukocytes to the CNS (adhesion, chemoattraction) are themselves modulated during the process of neuroinflammation [40] . Leukocyte migration across BBB endothelial cells involves both paracellular (at intercellular contact points) and transcellular migration [41] . Carman et al. demonstrated that upon contact with leukocytes, endothelial cells reorganize their membranes, creating 'cuplike' microdomains enriched with ICAM-1 and VCAM-1 microvilli projections that surround the transmigrating leukocytes and allow the transendothelial passage of an intact leukocyte to the abluminal side of the endothelial cell, without damaging the barrier [42] . ICAM-1 signals via the Rho pathway to regulate the endothelial actin cytoskeleton and possibly the formation of microvilli structures that favors transcellular passage of leukocytes. We believe that anti-VLA-4 therapy (natalizumab) [43] primarily impacts on the movement of immune cells within the extracellular matrix (basal lamina) surrounding the BBB-endothelial cells rather than on migration of leukocytes across endothelial cells per se. This matrix is composed of collagen, fibronectin, entactin and laminin 8 and 10, each of which is known to be a potent ligand for integrins, such as VLA-4 (a4 integrin).
IFNb and glatiramer acetate therapies also impact on BBB trafficking. In our in-vitro migration assay, IFNb reduces the migration of monocytes [44] and of Th1 but not Th2 lymphocytes [45] through human brain endothelial cells. IFNb also stabilizes BBB permeability and decreases the passage of soluble molecules across bovine brain endothelial cells [46] . Glatiramer acetate induces a significant increase in the migration of Th2 cells across human brain endothelial cells [45] .
Central nervous system related events
Within the CNS parenchyma, microglia can serve as antigen presenting cells, a function dependent on their state of activation. Activation of microglia/macrophages, the major CNS phagocytes, is also an important determinant of their capacity to remove damaged tissues, a prerequisite for optimal tissue repair [47] . Activation is upregulated or downregulated by 'danger' (infection/immune related) or 'stranger' (tissue injury) signals derived from their environment [48] . Ingestion of apoptotic T cells downregulates activity, representing a potential means to terminate the initial inflammatory response [49] . T cell signaling of microglia/macrophage mediated via specific cell surface molecule interactions (CD40:CD154) and proinflammatory cytokines results in upregulation of molecules involved in chemoattraction and antigen presentation. Ingestion of myelin debris, especially if opsonized with immunoglobulin, activates microglia [50] . Stressed or injured neurons release an array of cyclic nucleotides that can interact with purinergic receptors expressed on microglia, resulting in release of proinflammatory cytokines [51] .
Although none of the currently approved therapies for MS directly accesses the CNS, Kim et al. [52 ] showed that T cells polarized toward the Th2 cytokine, as can be achieved with glatiramer acetate, can impact on antigen presenting cells in the systemic compartment (monocytes) or CNS (microglia) so that naïve T cells to which they present antigen will be biased towards a Th2 phenotype. Minocycline (now in clinical trials for MS) [53] was shown to downregulate microglia activity in both neuroinflammatory and neurodegenerative disease models [54] . Other cells identified within the inflamed CNS and that can contribute to antigen presentation include dendritic cells and blood-borne monocytes that could have the capacity to convert into dendritic cell-like cells when migrating into the CNS [44, 55, 56] .
A hallmark of MS is the persistence of intrathecal immunoglobulin production, the majority of which does not seem to be neural specific. Ectopic lymphoid follicle-like structures with active germinal centers, now a recognized feature of the meninges in secondary progressive MS, provide a potential source of ongoing B cell responses that need not be disease antigen specific [57 ,58 ] . One speculates whether these meningeal structures underlie some of the recently observed pathology in superficial gray matter regions [59] . Specific antibodies may be generated subsequent to tissue injury as for example antineurofilament antibodies which presumably arise secondary to axonal injury in secondary progressive MS patients [60] and antibodies reactive with intracellular molecules (ribonucleoproteins) presumably reflecting leakage of intracellular neuronal proteins [61] . Their role in subsequent disease course remains to be shown.
The above observations all contribute to the changing view regarding the CNS as being a site of immunological privilege. Following an initial immune reaction within the brain, a cascade of immunological phenomena can be triggered that favor the perpetuation of antigen specific reactivity and the formation of follicle-like structures within the CNS, leading to the chronic breach of this immune privilege. Conversely, active mechanisms can suppress such responses; they may also be subject to therapeutic modulation.
The basis of the continued tissue injury and loss over time in MS continue to be defined. The lesions associated with the late progressive phases of MS seem more dominated by microglia/macrophage response than by lymphocytic infiltrates. We postulate that the accumulating tissue loss could reflect the impact of multiple recurrent insults with initially injured cells being more susceptible to subsequent effector molecules (multiple hit hypothesis). We found that human oligodendrocyte overexpressing p53 in vitro, as occurs in response to an array of insults and as seen in situ in MS tissues, makes them more susceptible to TRAIL and fas mediated injury [62] . Chronic demyelination itself impacts on axonal survival as a result of redistribution of sodium channels that permit calcium influx [63 ,64 ] .
Progression of disease due to failure of repair/ regeneration
Initial recovery from injury in MS may reflect at least in part progenitor cell dependent regenerative processes. Such cells may themselves be affected by the disease process. Selectivity of progenitor cell injury has been linked with their expression of maturation related surface molecules or receptors that determine their functional responses to specific antibodies [65, 66] , potential injury mediating molecules (glutamate) present in MS lesions [67, 68] , and trophic factors such as a low affinity p75 receptor for proNGF [69] [70] [71] .
Conclusion
Our opinion is that a T cell guided immune response, whether induced by systemic molecular mimicry responses or antigen release from events within the CNS, remains a central event in the initiation of the acute MS lesions, consistent with observations that therapeutically targeting these cells or their access to the CNS favorably impacts on the disease course. References and recommended reading This provides evidence of an immunologic response that distinguishes these entities; its role in disease pathogenesis will be defined.
